Used in research settings as a selective antagonist for sigma receptors, particularly showing affinity for the sigma-1 receptor subtype. It is employed to study neurological pathways and conditions such as neuropathic pain, addiction, and neurodegenerative diseases. Due to its ability to cross the blood-brain barrier, it is valuable in central nervous system pharmacology studies. AFPA helps in understanding receptor function and contributes to the development of therapeutic agents targeting psychiatric and neurological disorders.